Pharsight

Tekturna patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617595 NODEN PHARMA Galenic formulations of organic compounds
Feb, 2026

(1 year, 10 months from now)

US8617595

(Pediatric)

NODEN PHARMA Galenic formulations of organic compounds
Aug, 2026

(2 years from now)

Tekturna is owned by Noden Pharma.

Tekturna contains Aliskiren Hemifumarate.

Tekturna has a total of 2 drug patents out of which 0 drug patents have expired.

Tekturna was authorised for market use on 05 March, 2007.

Tekturna is available in tablet;oral dosage forms.

The generics of Tekturna are possible to be released after 19 August, 2026.

Drugs and Companies using ALISKIREN HEMIFUMARATE ingredient

Market Authorisation Date: 05 March, 2007

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of TEKTURNA before it's drug patent expiration?
More Information on Dosage

TEKTURNA family patents

Family Patents